Analyst Price Target is $3.50
▲ +343.04% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Diffusion Pharmaceuticals in the last 3 months. The average price target is $3.50, with a high forecast of $3.50 and a low forecast of $3.50. The average price target represents a 343.04% upside from the last price of $0.79.
Current Consensus is
The current consensus among 1 investment analysts is to hold stock in Diffusion Pharmaceuticals. This Hold consensus rating has held steady for over two years.
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company is also developing DFN-529, a phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway inhibitor. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.